Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia

Arellano‐Rodrigo, Eduardo; Alvarez‐Larrán, Alberto; Reverter, Joan Carles; Villamor, Neus; Jou, Josep M.; Cervantes, Francisco

doi:10.3109/09537104.2011.630112

Cited by 13 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with Arellano-Rodrigo E ‘s study [23] for ET patients, PDW and MPV were higher in mutated patients than those in wild-type patients in our study, and we also found that P-LCR was higher in mutant group. Since large platelet represented new and immature platelet, our results were consistant with Panova-Noeva M’s study [29], which showed that JAK2 V617F mutation was significantly associated with the increase of immature platelets.…”

Section: Discussionsupporting

confidence: 92%

“…Therefore, the relationship between JAK2 V617F and hemogram variation was controversial, and no investigation has been performed to determine the JAK2 V617F mutation rate in patients groups classified by RBC counts, WBC counts, platelet counts and lineage hyperplasia state. Besides, when considering platelet parameters, most studies focused on thrombopenia, there has been only one study [23] exploring the relationship between JAK2 V617F mutation and platelet parameters in ET patients, including platelet distribution width (PDW) and mean platelet volume (MPV).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

Zhou

Zeng

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundNon-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients’ hemogram variation remains not clear.MethodsJAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR).ResultsOf the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P25–P75): 45.02%(35.12%–54.22%)] than in essential thrombocythemia (ET) patients [median(P25–P75): 28.23%(17.77%–41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = −0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts.ConclusionsJAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

Zhou

Zeng

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…According to the Arellano-Rodrigo E's study [28] for ET patients, PDW and MPW were higher in patient with mutation than those in patients without mutation. Similarly we have found that MPV is significantly higher, PDW is higher with no significance in mutated patients.…”

Section: Discussionmentioning

confidence: 88%

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis

et al. 2014

View full text Add to dashboard Cite

Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia and thrombocytes are increased with abnormal functions. Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of the pathogenetic mechanisms of MPNs. Acquired single point mutation in the JAK2 V617F was determined approximately 50-60 % of patients with ET. In this study we aimed to investigate the relationship between JAK2 V617F gene mutation, hematologic, biochemical markers and the complications in the ET patients. A total of 268 patients diagnosed with ET and 219 of those studied for JAK2 gene mutation were followed at the hematology clinics of three major hospitals between 2008 and 2013 were screened retrospectively. Laboratory, clinical and hematologic parameters were compared for JAK2 V617F positive and JAK2 V617F negative patients with ET. 102 (46 %) patients were positive with the JAK2 V617F mutation. The complications were observed in 61 (28 %) patients and 38 (62 %) of them had JAK2 V617F mutation. The levels of white blood cells, neutrophil, basophil, red blood cells, hemoglobin, hematocrit, mean platelet volume, thrombocytes, eosinophil; urea, creatinine were significantly different in patients with the JAK2 V617F mutation (P < 0.05). Presence of the JAK2 V617F mutation supports the diagnosis of ET. It would be useful to investigate the JAK2 V617F mutation and the hematologic and biochemical markers at diagnosis with respect to consider the risk of developing complications and to take the precautions against these complications.

show abstract

“…Blood picture parameters and hemostatic tests in patients with essential thrombocythaemia with thrombosis (A) and in controls Parameter 18 observed that ET patients had higher values of MPV, especially those with JAK2 mutation. 18 At a multivariate study it has been confirmed that ET patients with thrombosis had a significantly higher percentage of reticulated platelets. Increased neutrophil and platelet activation play an important role in the pathogenesis of thrombotic complications in ET patients.…”

Section: Discussionmentioning

confidence: 99%

Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study

Prajs

Kuliczkowski

2017

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia

Cited by 13 publications

References 30 publications

Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis

Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study

Contact Info

Product

Resources

About